Ophthalmology, biologics, and eye disease treatment by Outlook Therapeutics
Outlook Therapeutics advances new therapies to improve retinal disease care
Outlook Therapeutics is accelerating work on innovative ophthalmic therapies aimed at improving care for patients with retinal diseases. The company states that preserving vision remains its core ...
U.S. FDA receives ONS-5010 Biologics License Application from Outlook Therapeutics
Outlook Therapeutics has announced the resubmission of its Biologics License Application to the U.S. FDA for ONS-5010/LYTENAVA (bevacizumab-vikg), a therapy candidate aimed at treating retina ...
Outlook Therapeutics prices 5 million direct offering at market under Nasdaq rules
Outlook Therapeutics has announced the pricing of a 5.0 million dollar registered direct offering that is priced at-the-market under Nasdaq rules. The fundraising move aims to bolster the ...
Appeal victory positions Outlook Therapeutics for ONS-5010 LYTENAVA progress
Outlook Therapeutics has secured a favorable outcome in the formal dispute resolution process concerning ONS-5010 LYTENAVA (bevacizumab-vikg) following an appeal. This decision marks a ...
Outlook Therapeutics request for FDA dispute resolution on ONS-5010 accepted
Outlook Therapeutics announced that the U.S. Food and Drug Administration has accepted its formal dispute resolution request related to ONS-5010/LYTENAVA, also known as bevacizumab-vikg. This ...
Outlook Therapeutics closes 5.0 million dollar public offering to boost capital
Outlook Therapeutics has successfully closed a public offering, raising 5.0 million dollars. The company aims to strengthen its financial position with the additional capital. The proceeds from ...
Outlook Therapeutics announces proposed public offering sending shares into focus
Outlook Therapeutics has announced plans for a proposed public offering. The move signals the companys intention to raise additional capital from investors. The offering, if completed, would ...
FDA meeting prompts new ONS-5010 update, Outlook Therapeutics outlines
Outlook Therapeutics has provided a new update following its Type A meeting with the Food and Drug Administration concerning ONS-5010/LYTENAVA, also known as bevacizumab-vikg. The company is ...
Outlook Therapeutics seeks FDA meeting after response letter
Outlook Therapeutics has submitted a Type A meeting request to the U.S. Food and Drug Administration (FDA) following a Complete Response Letter. The request aims to address FDA concerns and ...
